DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.

The Translational Genomics Research Institute, Phoenix, AZ, USA.
Cancer Research (Impact Factor: 9.28). 09/2010; 70(17):6934-44. DOI: 10.1158/0008-5472.CAN-10-0282
Source: PubMed

ABSTRACT Multiple myeloma (MM) is a plasma cell malignancy of the bone marrow, which evolves from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS). In some patients, an intermediate stage referred to as smoldering multiple myeloma (SMM) is clinically recognized, with the full-bore malignancy termed MM. We conducted a study to assess differential CpG methylation at 1,500 genic loci during MM progression and profiled CD138(+) plasma cells from MGUS, SMM, and MM specimens; human myeloma cell lines; and normal plasma cell (NPC) samples. We showed that the number of differentially methylated loci (DML) increased with tumor grade, and the vast majority were due to hypomethylation. Hierarchical clustering analysis revealed samples that coclustered tightly with NPC. These cases, referred to as "normal-like," contained significantly fewer DML when compared with their non-normal-like counterparts and displayed overall methylation levels resembling NPC. This study represents one of the first methylome interrogation studies in MM and points toward global hypomethylation at genic CpG loci as an important and early mechanism driving myelomagenesis. Determining the set of critical genes and pathways based on the myeloma methylome is expected to lead to an improved understanding of biological mechanisms involved in myelomagenesis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The current study aims to elucidate the epigenetic mechanisms by which genistein maintains a normal level of WNT genes during colon cancer development. We have reported that soy protein isolate (SPI) and genistein (GEN) repressed WNT signaling, correlating with the reduction of preneoplastic lesions in rat colon. We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5, and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period. We identified that in the post-AOM period the acetylation of histone H3 (H3Ac) was downregulated by SPI and GEN at the promoter region of Sfrp2, Sfrp5, and Wnt5a, which was in parallel with the reduced binding of RNA Polymerase II. Nuclear level of histone deacetylase 3 (HDAC3) was enhanced by SPI and GEN. The diets suppressed the trimethylation of histone H3 Lysine 9 (H3K9Me3) and the phosphorylation of histone H3 Serine 10 (H3S10P). Methylation of the specific region of Sfrp2, Sfrp5, and Wnt5a genes was increased by SPI and GEN, which was inversely correlated with the reduction of gene expression. Bisulfite sequencing further confirmed that dietary genistein induced DNA methylation at CpG island of the promoter region of Sfrp5. Importantly, this region includes a fragment that had decreased acetylation of histone H3. Here we present a potential epigenetic mechanism by which dietary genistein controls the responses of WNT genes during carcinogen induction, which involves DNA methylation, histone modifications, and their interactions at the regulatory region of gene.
    Carcinogenesis 04/2013; · 5.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes and copy number alterations and discovered putative tumor suppressor genes by determining homozygous deletions and loss of heterozygosity. We observed frequent mutations in KRAS (particularly in previously treated patients), NRAS, BRAF, FAM46C, TP53, and DIS3 (particularly in nonhyperdiploid MM). Mutations were often present in subclonal populations, and multiple mutations within the same pathway (e.g., KRAS, NRAS, and BRAF) were observed in the same patient. In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and even growth promotion of nonmutated subclones in some cases. These results emphasize the importance of heterogeneity analysis for treatment decisions.
    Cancer Cell 01/2014; 25(1):91-101. · 24.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple research groups have observed neuropathological phenotypes and molecular symptoms in vitro using induced pluripotent stem cell (iPSC)-derived neural cell cultures (i.e., patient-specific neurons and glia). However, the global differences/similarities that may exist between in vitro neural cells and their tissue-derived counterparts remain largely unknown. In this study, we compared temporal series of iPSC-derived in vitro neural cell cultures to endogenous brain tissue from the same autopsy donor. Specifically, we utilized RNA sequencing (RNA-Seq) to evaluate the transcriptional progression of in vitro-differentiated neural cells (over a timecourse of 0, 35, 70, 105, and 140 days), and compared this to donor-identical temporal lobe tissue. We observed in vitro progression towards the reference brain tissue, and the following three results support this conclusion: (1) there was a significant increasing monotonic correlation between the days of our timecourse and the number of actively transcribed protein-coding genes and long intergenic noncoding RNAs (lincRNAs) (p<0.05), consistent with the transcriptional complexity of the brain; (2) there was an increase in CpG methylation after neural differentiation that resembled the epigenomic signature of the endogenous tissue; and (3) there was a significant decreasing monotonic correlation between the days of our timecourse and the percent of in vitro to brain tissue differences (p<0.05) for tissue-specific protein-coding genes and all putative lincRNAs. Taken together, these results are consistent with in vitro neural development and physiological progression occurring predominantly by transcriptional activation of downregulated genes rather than deactivation of upregulated genes.
    Human Molecular Genetics 05/2013; · 7.69 Impact Factor


Available from